Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Manasa, Justen, Varghese, Vici, Pond, Sergei L. Kosakovsky, Rhee, Soo-Yon, Tzou, Philip L., Fessel, W. Jeffrey, Jang, Karen S., White, Elizabeth, Rögnvaldsson, Thorsteinn, Katzenstein, David A., Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599673/
https://www.ncbi.nlm.nih.gov/pubmed/28912582
http://dx.doi.org/10.1038/s41598-017-11893-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599673/
https://www.ncbi.nlm.nih.gov/pubmed/28912582
http://dx.doi.org/10.1038/s41598-017-11893-8

Ejemplares similares